Table 1.
Basic characteristics of the included studies
| Study | Country | Patients | Methods | Primary aim | Methylation site | CDH13 expression |
|---|---|---|---|---|---|---|
| Kontic et al44 | Serbia | 65 | MSP | Determine the frequency of CDH13 hypermethylation in NSCLC | Promoter, CpG islands | – |
| Zhang et al55 | People’s Republic of China | 78 | MSP | Determine the methylation status of multiple genes in NSCLC | Promoter, CpG islands | – |
| Kubo et al56 | Japan | 100 | MSP | Determine the methylation status of five tumor suppressor in NSCLC | Promoter, CpG islands | – |
| Feng et al57 | United States | 49 | DNA methylation (MethyLight) analysis | Determine the clinical significance of seven tumor suppressors in NSCLC | Promoter, CpG islands | – |
| Brock et al23 | United States | 79 | MSP | Determine the association between gene methylation and recurrence in NSCLC | Promoter, CpG islands | – |
| Wang et al58 | People’s Republic of China | 28 | DNA microarray-coupled polymerase chain reaction | Determine 15 genes’ methylation status in NSCLC | Promoter, CpG islands | – |
| Kim et al50 | South Korea | 88 | MSP | Determine the role of CDH13 in pathogenesis of NSCLC | Promoter, CpG islands | – |
| Hsu et al59 | People’s Republic of China | 63 | MSP | Determine methylation patterns of six tumor suppressor gene in NSCLC | Promoter, CpG islands | – |
| Suzuki et al54 | Japan | 150 | MSP | The methylation profile of nine genes for NSCLC were analyzed and correlated with clinical data | Promoter, CpG islands | – |
| Ulivi et al60 | Italy | 61 | MSP | Detection of promoter methylation of p16INK4A and CDH13 genes in NSCLC | Promoter, CpG islands | – |
| Toyooka et al26 | United States | 42 | MSP | Analyze DNA methylation status of CDH13 gene in NSCLC patients | Promoter, CpG islands | + |
Abbreviations: NSCLC, nonsmall cell lung cancer; MSP, methylation-specific polymerase chain reaction.